Axsome Therapeutics (AXSM): Valuation Insights Following Analyst Coverage and Anticipated Regulatory Milestones

Axsome Therapeutics (AXSM) has drawn fresh attention after B. Riley Securities initiated coverage, citing the company’s solid revenue growth, efficient operations, and several significant regulatory and pipeline milestones expected over the next year.

See our latest analysis for Axsome Therapeutics.

Momentum for Axsome Therapeutics has been picking up, with the share price recently closing at $119.94 and a solid 1-year total shareholder return of 32%. The initiation of analyst coverage comes following faster revenue growth from lead drugs, a pending regulatory submission for Auvelity in Alzheimer’s agitation, and a fresh competitive challenge related to generics, setting the stage for an eventful year ahead.

If this mix of new developments has you interested in what else is happening across healthcare, now’s a good time to expand your search and explore See the full list for free.

With shares up more than 30% over the past year and analysts calling for even more upside, the critical question is whether Axsome Therapeutics is still undervalued or if all this growth is already reflected in the stock price.

Most Popular Narrative: 32.2% Undervalued

The narrative suggests Axsome Therapeutics could have significant upside from its last close of $119.94, with a fair value target of $176.84. The gap between the current price and projected value reflects optimism around product launches, commercial execution, and a rapidly expanding pipeline.

“Axsome’s portfolio is expanding with the launch of SYMBRAVO for migraine and ongoing robust growth of Auvelity and Sunosi. This reflects increased societal prioritization of mental health and CNS disorders, which could drive further top-line revenue growth as these long-term demand trends play out globally.”

Read the complete narrative.

Curious what bold projections get analysts to such a high target? The future valuation hinges on breakout growth for every key product and a dramatic margin turnaround. The most surprising financial expectations behind this narrative will make you question just how fast this company can scale.

Result: Fair Value of $176.84 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, investors should watch for slow product launches and pricing pressure, as either could limit Axsome’s upside and challenge those bullish long-term forecasts.

Find out about the key risks to this Axsome Therapeutics narrative.

Another View: Our DCF Model Paints a Dramatically Different Picture

While price-to-sales ratios suggest Axsome Therapeutics sits on the higher end compared to industry norms, our SWS DCF model delivers a much more bullish verdict. According to this approach, Axsome could be trading well below its true worth. Could the market be overlooking long-term value, or are assumptions too optimistic?

Look into how the SWS DCF model arrives at its fair value.

Build Your Own Axsome Therapeutics Narrative

If you see the outlook differently or want to dig deeper into the numbers, it only takes a few minutes to build your own perspective. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Axsome Therapeutics.

Looking for More Investment Ideas?

Don’t miss out on the potential that awaits. Expand your watchlist and put your capital to work with smart opportunities only a few clicks away.

• Boost your portfolio’s income stream by targeting reliable yields with these 19 dividend stocks with yields > 3%, packed with companies offering dividends above 3%.
• Tap into artificial intelligence’s explosive growth through these 24 AI penny stocks and uncover companies riding the AI revolution.
• Seize the potential to buy low with these 909 undervalued stocks based on cash flows, connecting you to stocks trading below their true value based on future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com